{"id":"W2117985979","doi":"10.1093/annonc/mds503","title":"A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pfizer (Canada); University of Toronto; Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal; London Health Sciences Centre; Hôpital Notre-Dame","funders":"Pfizer","keywords":"Medicine; Discontinuation; Internal medicine; Clinical endpoint; Adverse effect; Mucositis; Phases of clinical research; Gastroenterology; Toxicity; Response Evaluation Criteria in Solid Tumors; Oncology; Diarrhea; Clinical trial; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004591817,0.0001730971,0.001004112,0.00009896456,0.00007127469,0.000001547324,0.00005966236,0.0000852514,0.00005920392],"category_scores_gemma":[0.0001748932,0.0001055455,0.00009625893,0.0001414683,0.0002649835,0.00006313172,0.00008010691,0.0001138606,6.378086e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004931505,"about_ca_system_score_gemma":0.0002155078,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009674272,"about_ca_topic_score_gemma":0.001909337,"domain_scores_codex":[0.9985298,0.0002309178,0.0006255902,0.0001929997,0.0001451071,0.0002755651],"domain_scores_gemma":[0.9990163,0.0002469857,0.0002894044,0.000217508,0.00009771467,0.0001320159],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1967374,0.2000128,0.07477076,0.001716406,0.0004978754,0.00005986652,0.04847382,0.000001405313,0.027473,0.0003666029,0.007940632,0.4419494],"study_design_scores_gemma":[0.2596375,0.6005063,0.02213085,0.0002972477,0.0004522028,0.00003129925,0.001728453,0.00002587228,0.06696571,0.0000881646,0.04790143,0.0002349619],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924176,0.002999139,2.453557e-7,0.002773933,0.000244932,0.0009207673,0.00005926956,0.000004875245,0.0005791928],"genre_scores_gemma":[0.9984345,0.0008089161,0.0001194108,0.0002406027,0.0001627026,0.0000736607,0.000013954,0.00001294473,0.0001333354],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4417145,"threshold_uncertainty_score":0.4304022,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1637312590794041,"score_gpt":0.4497710802575013,"score_spread":0.2860398211780972,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}